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ABSTRACT  
Hypothesis 
Gemini pyridinium-based amphiphiles can play a triple role as: gold nanoparticles (AuNPs) 
synthesis facilitator, particle stabilizer and anion recognition centre. The so formed nanoparticles 
should be able to bind and release anionic drugs.  
Experiments 
 We describe (a) Synthesis, by a phase transfer method, of both new organic media and water 
soluble AuNPs using gemini-type surfactants based on bis-pyridinium salts as ligands, acting as 
transfer agents into organic media and also as nanoparticle stabilizers, (b) Examination of their 
stability in solution, (c) Chemical and physical characterization of the nanoparticles, (d) Toxicity 
data concerning both the bis-pyridinium ligands and the bis-pyridinium coated nanoparticles, and 
(e) Study of their ability for delivering anionic pharmaceuticals such as ibuprofen and piroxicam.  
Findings 
Pyridinium gemini-type surfactants show the ability to play multiple roles such as transfer agent 
and stabilizer, as well as ionophores: They are responsible for the preparation, stability, and 
delivery properties of these AuNPs, which gold core is stabilized by the anions present in the bis-
pyridinium salts. The tetrahydropyridine resulting from the reduction of the pyridinium salt is 
capable of reduce gold, due to its spontaneous oxidation to the corresponding pyridinium salt, 
leading to the formation of stable AuNPs.  
 
 
Keywords: Gemini pyridinium amphiphiles, tetrahydropyridines, gold nanoparticles, anionic 
drug encapsulation  
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1. Introduction 
Gold nanoparticles (AuNPs) are one of the most investigated metal nanoparticles.[1,2] They have 
attracted considerable interest in various applications such as catalysis,[3,4]  medical diagnosis,[5] 
biological sensors,[6] drug delivery[7,8] and imaging.[9]  Many types of ligands have been studied 
as stabilizers in the synthesis of organic and water soluble AuNPs: besides thiols, other examples 
found in the literature include thioether end-functionalized polymers,[10] dendrimers,[11] amino 
acid based amphiphiles,[12] peptides,[13] DNA,[14] and ionic liquids based on imidazolium 
salts.[15] In particular, the use of derivatives of pyridine such as 4-(dimethylamino)pyridine 
(DMAP),[16–18] dihydropyridine[19] and pyridinium salts[20,21] as stabilizing agents of AuNPs 
has been reported although the definitive stabilization mechanism is not yet fully established.  
On the other hand, our group has reported previously the preparation and stabilization of 
monodisperse gold nanoparticles using gemini imidazolium-based amphiphiles.[22,23]  These 
molecules show anion binding properties in solution, and therefore they play a unique triple role, 
acting as phase transfer agent of the gold salt during the synthesis, capping agent for the 
stabilization of the AuNPs, and binding agent for anionic molecules, resulting in a major 
simplification of the synthetic process and subsequent purification of the functional 
nanomaterial.[22] Furthermore, the ability of bis-imidazolium salts to complex anions,[24] 
particularly carboxylates, allowed the incorporation and delivery of a carboxylate-containing 
model drug.[22,25]  
As a step forward in this research we have focused on the use of gemini amphiphiles based on bis-
pyridinium salts in the synthesis of AuNPs, expecting that these molecules would expand the anion 
recognition ability of the nanomaterials. To test the AuNPs’ ability to incorporate and release 
anionic molecules, two model drugs were used: ibuprofen and piroxicam, which are non-steroidal 
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anti-inflammatory drugs widely used in inflammatory arthritis and osteoarthritis.[26] The gemini 
pyridinium salts used in this work are formed by two pyridinium rings linked by a 1,3-
dimethylenebenzene spacer. This spacer was chosen based in analogue compounds that contain 
pyridinium moieties rather than imidazolium. Therefore, to study the effect of the spacer (length 
and flexibility) lies beyond the scope of the present work. 
Thus, we report here (a) a solution based preparation of new AuNPs (organic and water-soluble 
AuNPs) with bis-pyridinium amphiphilic ligands, which act both as transfer agents of gold into 
organic media and also as nanoparticle stabilizers, (b) the formation of AuNPs by reduction of Au 
3+ by the spontaneous oxidation of a bis-tetrahydropyridine amphiphile, (c) their chemical and 
physical characterization, including their stability in solution toward aggregation and ligand 
exchange, (d) toxicity data concerning both the bis-pyridinium ligands and the bis-pyridinium 
coated nanoparticles, (e) their molecular recognition ability toward piroxicam and ibuprofen, as 
models of anionic drugs, (f) in vitro studies of the ability of the new AuNPs for delivering anionic 
pharmaceuticals. 
 
2. Experimental Section 
2.1. Materials  
Sodium hydrogen carbonate, sodium sulfate (Na2SO4) and 6N hydrochloric acid (HCl) were 
purchased from Scharlau; sodium hydroxide (NaOH) from Merck, 4-methylpyridine, 1,3-
bis(bromomethyl)benzene, 1-decanol, 1-octadecanol, 4-chloropyridine hydrochloride, hydrogen 
peroxide (H2O2), sodium borohydride (NaBH4), hydrogen tetrachloroaurate (III) (HAuCl4), 
sodium citrate tribasic dihydrate, potassium bromide (KBr), ibuprofen, piroxicam, 
tetraoctylammonium bromide, phosphate buffered saline (PBS) pH=7.4 and 5.2 were purchased 
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from Sigma-Aldrich. Metallic sodium and ammonia 20 % were purchased from Panreac and 
hexa(ethylene glycol)alkyl thiol (HS-C11-(EG)6-OH) was purchased from Prochimia. Acetonitrile 
(MeCN), dichloromethane (CH2Cl2), methanol (MeOH), diethyl ether (Et2O), chloroform 
(CHCl3), ethanol (EtOH), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), 
dimethylformamide (DMF), toluene, dimethylsulfoxide-d6 (CD3)2SO and chloroform-d (CDCl3) 
were purchased from Sigma-Aldrich.  
 
2.2. Methods  
Melting points were measured by CTP-MP 300 hot-plate apparatus with ASTM 2C thermometer 
using crystal capillaries purchased from Afora. 1H NMR: Varian Gemini 300 (300 MHz), Varian 
Mercury 400 spectrometers (400 MHz) from Centres Científics i Tecnològics de la Universitat de 
Barcelona (CCiT-UB). 13C-NMR: Varian Mercury 400 (100 MHz) from CCiT-UB. NMR spectra 
were determined in CDCl3 or (CD3)2SO with tetramethylsilane (TMS) as reference. The chemical 
shifts are expressed in parts per million (ppm) relative to the central peak of the solvent. Infrared 
Spectroscopy (IR): IR spectra were collected on a Thermo Nicolet Avatar 320 FT-IR spectrometer 
at room temperature in the range 4000-400 cm-1, in KBr pellets (1 % of the samples). Elemental 
analysis was performed on a Thermo EA 1108 CHNS from CCiT-UB. Thin layer chromatography 
was performed on a Merck coated F254 silica gel plates. Column chromatography was carried on 
silica gel 60 (Merck 9385, 230-400 mesh). Matrix Assisted Laser Desorption Ionization-Time of 
Flight Mass Spectrometry (MALDI-ToF-MS) analysis were performed using a Voyager-DE-RP 
(Applied Biosystem, Framingham, USA) mass spectrometer, and High Resolution Mass 
Spectrometry (HRMS) were obtained by Electrospray Ionization (ESI) on a LC/MSD-ToF mass 
spectrometer (Agilent Technologies, 2006) from CCiT-UB. MS analysis was operated in the 
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delayed extraction mode using 2,5-dihydroxybenzoic acid (DHB) as a matrix. UV absorption 
spectra were obtained using UV-1800 Shimadzu UV spectrophotometer, using quartz cuvettes 
with a 1 cm path length. Absorption spectra were determined in CHCl3 and H2O. High-Resolution 
Transmission Electron Microscopy (HRTEM): The images were obtained using a JEOL JEM 2100 
transmission electron microscope at 200 kV, from CCiT-UB. The protocol to prepare the samples 
for the HRTEM and experimental details of the cytotoxicity and genotoxicity, incorporation of 
drugs into AuNPs and the release study are explained in the Supplementary Material Section 1. 
The images were captured by a Mega view III Soft Imaging System camera, and the size of the 
nanoparticles gold core was measured with ImageJ.[27] The size of the nanoparticles was also 
determined by Dynamic Light Scattering (DLS) using a Zetasizer Nano ZS series (Malvern 
Instruments) from Departament de Farmàcia i Tecnologia Farmacèutica i Fisicoquímica, 
Universitat de Barcelona. XPS experiments were performed at Institut Català de Nanociència i 
Nanotecnologia (ICN2)-CSIC in a Phoibos 150 analyzer (SPECS GmbH, Berlin, Germany)) in 
ultra-high vacuum conditions (base pressure 5E-10 mbar) with a monochromatic aluminium 
Kalpha x-ray source (1486.74eV). ). The energy resolution as measured by the FWHM of the Ag 
3d5/2 peak for a sputtered silver foil was 0.58 eV. Thermogravimetric Analysis was performed on 
Mettler Toledo TGA/SDTA 851e from CCiT-UB, from 30 °C to 700 °C with a heating rate of 10 
°C min-1. Capsules: crucible of aluminum (100 μL) with perforated cap. Nitrogen was used as 
purgative gas in all measurements. 
 
 
2.3. Synthesis and characterization of the ligands 1·2Br and 2 
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1,3-Bis(4-octadecyloxy-1-piridiniomethyl)benzene dibromide (1·2Br): The synthesis of the 
precursor of 1·2Br followed a modification of a protocol previously reported,[28] where metallic 
sodium (1.86 g, 80 mmol) was added to 1-octadecanol (21.9 g, 80 mmol) at 110 °C for 2 h. Then 
4-chloropyridine hydrochloride (4.95 g, 33 mmol) was added and the mixture was stirred for 72 h 
at 110 °C. After cooling down to room temperature, water (50 mL) was added dropwise and the 
solution neutralized with HCl 6N. The aqueous phase was extracted with CH2Cl2 (4 x 25 mL), and 
the organic phase was dried with anhydrous Na2SO4 and the solvent was evaporated in vacuum. 
The residue was purified using a silica gel column chromatography using Et2O/CH2Cl2 (7:3) as 
eluent, following by column chromatography in CH2Cl2/MeOH (9:1), obtaining 4-
octadecyloxypyridine (2.66 g, yield 23 %) and used directly in next step.  
A solution of 4-octadecyloxypyridine (150 mg, 0.43 mmol) in dry MeCN (13 mL) was added 
dropwise during 1 h to a solution of 1,3-bis(bromomethyl)benzene (57 mg, 0.22 mmol) in dry 
MeCN (10 mL) and heated at 75 °C for 24 h. After cooling down to room temperature, the 
suspension was filtered off, and the white solid was washed with MeCN (5 mL) and dried to afford 
1·2Br (1.80 g, 94 %): mp> 300 °C. 1H-NMR (300 MHz, CDCl3, 25 °C): δ 9.76 (d, J = 7.5 Hz, 4H, 
H-2', '6), 8.39 (s, 1H, Ar-H2), 7.69 (d, J = 6.3 Hz, 2H, Ar-H 4, 6), 7.33 (d, J = 7.5 Hz, 4H, H- 3', 
5'), 7.01 (dd, J = 7.8 Hz, 1H, Ar-H5), 5.92 (s, 4H, N-CH2), 4.21 (t, J = 6.45 Hz, 4H, (O-(CH2)), 
1.25 (s, 64H, 2(CH2)16), 0.87 (t, J = 6.6 Hz, 6H, (CH3)). 
13C-NMR (100 MHz, CDCl3, 25 °C): δ 
170.4, (Py- C 4'), 146.9 (Py- C 2', 6'), 134.5 (Ar- C 1, 3), 131.3 (Ar- C2), 130.3 (Ar- C5), 130.1 
(Ar- C 4, 6), 113.9 (Py- C 3', 5'), 71.4 (O-CH2), 61.3 (N-CH2), 31.8-22.6 ((CH2)16), 14.1 (CH3). 
MALDI-ToF–MS m/z: 879.7 (100 %) [M-Br]+, 797.7 (85 %) [M-2Br]+, 530.4 (30 %) [M-
Br(C23H41NO)]
+, 450.5 (20 %) [M-((2Br)C23H41NO)]
+. HMRS (ESI) m/z: (C54H90N2O2Br2 -2Br)
2+ 
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calculated 399.3489 found 399.3496. Elemental analysis (C54H90Br2N2O2·1H2O): N (calculated 
2.92 found 3.01) C (calculated 66.38 found 66.81) H (calculated 9.49 found 9.58).  
1,3-Bis(4-octadecyloxy-1,2,5,6 tetrahydropyridylmethyl)benzene (2): A solution of NaBH4 (5 
mg, 0.13 mmol) in H2O (2 mL) was added to a solution of 1·2Br (25 mg, 0.03 mmol) in dry CH2Cl2 
(2 mL). The mixture was stirred during 1 h at room temperature. Then, the aqueous phase was 
extracted with CH2Cl2 (3 x 5 mL), and the organic phase was dried with anhydrous Na2SO4 and 
the solvent was evaporated in vacuum to afford 2 as a yellow oil 20 mg, 88 %. 1H-NMR (300 
MHz, CDCl3, 25 °C): δ 7.32 (s, 1H, Ar-H2), 7.26 (m, 3H, Ar-H 4, 5, 6), 4.54 (s, 2H, H5'), 3.61 (t, 
J = 7.06 Hz, 4H, (O-(CH2)), 3.56 (s, 4H, N-CH2), 3.03 (s, 4H, H 6'), 2.59 (t, J = 4.45 Hz, 4H, H 
2'), 2.20 (m, 4H, 2(CH2)), 1.64 (m, 4H, 2(CH2), 1.43-1.25 (s, 56H, 2(CH2)14), 0.88 (t, J = 6.0 Hz, 
6H, CH3). MALDI-ToF–MS m/z: 803.6 (100 %) [M-1] +, 454.3 (70 %) [M-(C31H52NO)]. HMRS 
(ESI) m/z: (C54H96N2O2) calculated 804.75 found 805.75. 
 
2.4. Synthesis and characterization of AuNPs  
2.4.1. Synthesis of 1·AuNPs with the bis-pyridinium salt 1·2Br  
A solution of HAuCl4 (11.8 mg, 0.03 mmol) in water (0.5 mL) and a 1% solution of trisodium 
citrate dihydrate (15 mg, 0.05 mmol) in water (1.5 mL) were added to boiling water (10 mL). 
Heating was continued for 15 min. during which time the solution changed colour from pale yellow 
to red. The reaction flask was allowed to cool to room temperature. Then, an aqueous solution of 
these AuNPs (8 mL) was mixed with a solution of ligand 1·2Br (24 mg, 0.025 mmol) in CHCl3 (8 
mL). The biphasic mixture was stirred for 24 h in the dark at room temperature. The phases were 
separated and the solvent of the organic phase was removed in a rotary evaporator, and the residue 
washed using centrifugation in EtOH (3 x 1 mL), to give 1·AuNPs.  
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2.4.2. Synthesis of 2·AuNPs with the bis-pyridinium salt 1·2Br  
An aqueous solution of HAuCl4 (8.8 mg, 0.026 mmol) in water (2 mL) was mixed with a solution 
of 1·2Br (50 mg, 0.052 mmol) in CHCl3 (2 mL). After 1 h, a solution of NaBH4 (4.9 mg, 0.13 
mmol) in water (2 mL) was slowly added. The stirring continued for 4 h in the dark at room 
temperature. The organic phase of the resulting dark red solution was separated and the solvent 
was removed in a rotary evaporator, and the residue washed using centrifugation in EtOH (5 x 1 
mL), to afford 2·AuNPs. 
 
2.4.3. Synthesis of 3·AuNPs and 4·AuNPs using the bis-pyridinium salt 1·2Br and the thiol 
HS-C11-(EG)6-OH  
A solution of HAuCl4 (3.6 mg, 0.009 mmol) in water (0.5 mL) was added to a stirred solution of 
1·2Br (4.3 mg, 0.005 mmol) in CHCl3 (0.5 mL). Then, a solution of the thiol HS-C11-(EG)6-OH 
(2.1 mg, 5 μmol) in CHCl3 (0.5 mL) was added. An excess of NaBH4 (5.1 mg, 0.14 mmol) in water 
(1 mL) was added dropwise to the mixture. The stirring continued for 24 h in the dark at room 
temperature. AuNPs were obtained in both phases (organic and aqueous phase). The water-soluble 
AuNPs were named 3·AuNPs and the organic-soluble AuNPs were named 4·AuNPs. The phases 
were separated and the solvent of aqueous phase (3·AuNPs) and organic phase (4·AuNPs) was 
removed in a rotary evaporator, and the residues washed using centrifugation in EtOH (5 x 1 mL). 
 
2.4.4. Synthesis of 2'·AuNPs with the tetrahydropyridine 2.  
A solution of 2 (50 mg, 62 μmol) in CHCl3 (2 mL) was added to a solution of KBr (15.3 mg, 0.13 
mmol) in water (2 mL). Then a solution of HAuCl4 (1.8 mg, 0.005 mmol) in water (2 mL) was 
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added dropwise to the mixture. The stirring continued for 3 h in the dark at room temperature. The 
phases were separated and the organic solvent was removed in a rotary evaporator, and the residue 
washed using centrifugation in EtOH (5 x 1 mL), to afford 2'·AuNPs. 
 
3. Results and Discussion 
The compounds synthesized in this work are bis-pyridinium salts connected through a 1,3-xylyl 
spacer; the pyridinium moieties bear chains of different length: 1·2Br (18 carbon atoms) (Figure 
1), 3·2Br (10 carbon atoms) and 4·2Br (1 carbon atom) (see Supplementary Material Figure S1), 
to assess the influence of the chain length on the synthesis and stability of the AuNPs where they 
will be incorporated. The three bis-pyridinium salts 1·2Br, 3·2Br and 4·2Br were synthesized in 
good yield (see Supplementary Material Scheme S1). Salts 1·2Br and 3·2Br were obtained in two 
steps by reaction of 4-chloropyridine hydrochloride with aliphatic alcoxides, either from 1-
octadecanol or 1-decanol, affording the corresponding alkoxypyridines,[28] which were the 
limiting step, since they were difficult to purify. The alkoxypyridines reacted with 1,3-
bis(bromomethyl)benzene to afford 1·2Br (94 %) and 3·2Br (83 %), respectively. Also, the 
tetrahydropyridine 2 was obtained in 88 % in yield by treatment of bis-pyridinium salt 1·2Br with 
an excess of NaBH4 (Figure 1 and Scheme S1 in Supplementary Material). The bis-pyridinium salt 
4·2Br was obtained in 97 % in yield by reaction of 4-methylpyridine with 1,3-
bis(bromomethyl)benzene (Scheme S1 in Supplementary Material). These newly synthesized bis-
pyridinium salts 1·2Br, 3·2Br and 4·2Br and the tetrahydropyridine 2 were characterized by 1H 
and 13C-NMR spectroscopy, MALDI-ToF-MS, IR and elemental analysis. The results of the 
different techniques used for the characterization of the ligands are shown in the Supplementary 
Material (Figure S2–S21).  
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Figure 1. Structures of compounds 1·2Br and 2 and their respective cartoons.  
Figure (1.5-column)  
 
3.1. Synthesis of AuNPs using 1·2Br and the tetrahydropyridine 2  
The schematic representation of the different AuNPs are shown in Scheme 1 and their synthesis 
method was selected depending of the solubility of the ligands 1·2Br and 2. The different 
experiments for their preparation are summarized in Table 1.  
Firstly, we synthesized AuNPs using the bis-pyridinium salt 1·2Br to study their capacity as 
stabilizer agent. Thus, 1·AuPs were obtained by a two-step procedure, consisting of the 
preparation of citrate stabilized NPs (using a modification of Turkevich method[29]), followed by 
mixing with a solution of the ligand 1·2Br for 24 h (Table 1 entry 1). The characterization of 
1·AuNPs (see later) indicates the presence of a bis-pyridinium salt coating the stabilized gold 
nanoparticles. 
On the other hand, the synthesis following a modification of AuNPs using the same bis-pyridinium 
salt 1·2Br as stabilizing agent and the biphasic Brust-Schiffrin protocol[30] resulted in a red 
solution, the so-formed AuNPs are named 2·AuNPs here (Table 1, entry 2). In this case, the 
reducing agent NaBH4 converts the pyridinium salt to the tetrahydropyridine 2, and therefore a 
1·2Br 2
Br
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mixed coating is expected for 2·AuNPs (Scheme 1). These results confirm the capacity of 1·2Br 
as stabilizer agent as well as transfer agent in the synthesis of the 1·AuNPs and 2·AuNPs.  
Additionally, the stability of 2·AuNPs was determined in solution at room temperature and under 
reflux in three different solvents (CHCl3, THF and toluene), by means of UV-vis absorption 
spectroscopy. No obvious change in the shape of the maximum in the plasmon resonance peak 
was observed, which indicates that the prepared 2·AuNPs are stable (Supplementary Material 
Section 3 Table S1). 
One concern during the synthesis of these AuNPs is the chemical integrity of the bis-pyridinium 
salt 1·2Br under the reaction conditions used, especially in the presence of NaBH4 as the reducing 
agent, because the reduction could lead to the formation of tetrahydropyridine species that could 
influence the stability of the AuNPs. The mechanism of the reduction of pyridinium salts by 
sodium borohydride to give tetrahydropyridine and piperidine derivatives has been well 
established.[31,32] It is known that dihydropyridines can act as coatings in the formation of stable 
gold nanoparticles,[19] while for tetrahydropyridines, to the best of our knowledge, have not been 
reported yet. 
To obtain water soluble AuNPs, with potential to be used in biomedical applications, some 
attempts were made to use both ligands in a monophasic system, but no AuNPs could be obtained, 
and therefore we chose to use a biphasic system adapted from the Brust-Schiffrin method. 
Basically, the AuNPs preparation consisted of mixing of the gemini pyridinium based amphiphilic 
ligand 1·2Br and a thiolated polyethyleneglycol derivative HS-C11-(EG)6-OH in CHCl3 for the 
formation and coating of AuNPs, and then adding the aqueous HAuCl4 solution and the reducing 
agent (NaBH4). Following this method, it was possible to obtain two types of AuNPs: Water-
soluble AuNPs named 3·AuNPs and organic-soluble AuNPs named 4·AuNPs (Table 1, entry 3). 
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The different hydrophilicity of 3·AuNPs and 4·AuNPs may originate on the relative proportion 
of both stabilizers, obviously with 3·AuNPs having a higher content on HS-C11-(EG)6-OH, but 
the exact proportion of each could not be exactly determined. The obtained 3·AuNPs and 
4·AuNPs will allow to study the incorporation and interaction with different anionic drugs such 
as ibuprofen and piroxicam and their respective sodium salts (see later).  
To confirm which species, either pyridinium salt 1·2Br or its reduced form 2, is stabilizing the 
gold surface, we encompassed different experiments (Table 1 entries 4 and 5). First, we attempted 
the synthesis of AuNPs using the tetrahydropyridine 2 following a modification of the Brust-
Schiffrin method but in the absence of the reducing agent NaBH4. Under these conditions, the bis-
tetrahydropyridine 2 is capable of reducing Au+3 to Au0, concomitantly to its spontaneous 
oxidation to the corresponding bis-pyridinium salt, leading to the formation of nanoparticles, 
which were unstable in solution as indicated by the formation of a dark precipitate after 24 h (Table 
1, entry 4). However, when the tetrahydropyridine 2 was used in the presence of an excess of KBr 
(Table 1, entry 5), stable 2'·AuNPs soluble in organic solvents were obtained. The stabilization of 
the metallic core by reduced 2 is proven by the fact that nanoparticles are not stable when 
synthetized from 2 with no addition of an excess of KBr. Additionally, the excess of pyridinium 
salts 1·2Br that are not coating the AuNPs, and therefore remains free in solution, is rapidly 
reduced to tetrahydropyridine 2 by action of the NaBH4 used as reducing agent, likely resulting in 
a formation of a bilayer around the pyridinium salts, although the exact disposition of 2 is not 
exactly determined. Due to the fact that the tetrahydropyridine does not have charges, these AuNPs 
are not water-soluble. If a 1·2Br bilayer was formed, the AuNPs would be water-soluble.   
 15 
 
Scheme 1. Schematic representation of the synthesis of the gold nanoparticles: a) 1·AuNPs, b) 
2·AuNPs, c) 3·AuNPs, d) 4·AuNPs an d) 2'AuNPs. Scheme (2-column) 
 
These experiments indicate that the stabilizing species around the gold core in the AuNPs is the 
ion pair formed by either bromide or citrate ions, attached to the gold particle surfaces, and the 
cationic surfactant head groups (gemini pyridinium salt) surrounding the anion layer by 
electrostatic interactions. This conclusion arises from the fact that when no enough bromide ions 
anions are present, i.e. when using only the tetrahydropyridine 2, the obtained AuNPs are not 
CHCl3, r.t, 24 h
Citrate AuNPs 1·AuNPs (organic-soluble)
HAuCl4/H2O+
1) H2O/CHCl3 , r.t, 1 h
2) H2O, NaBH4, r.t, 4 h
2·AuNPs (organic-soluble)
a)
b)
1) H2O/CHCl3
2) 
3) H2O, NaBH4, r.t, 24 h        
d)
+ KBr
1) CHCl3/H2O
2) HAuCl4/H2O
r.t, 3 h
2'·AuNPs (organic-soluble)
c)
3·AuNPs (water-soluble) 4·AuNPs (organic-soluble)
2
1·2Br
1·2Br
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sufficiently stable and flocculate. These results are in agreement with previous reports on the 
interaction of anions with a solution of metallic nanoparticles, and the ions’ role in the stabilization 
of metal nanoparticles.[33] All the above indicates that for the synthesis of stable AuNPs based on 
bis-pyridinium salts the presence of the anions in their structure is critically important. 
On the other hand, to study the influence of the length chain of the ligands on the stabilization of 
the AuNPs, we selected bis-pyridinium salts with shorter hydrocarbon chains: 3·2Br and 4·2Br 
(see Supplementary Material Figure S1). The synthesis of AuNPs using the bis-pyridinium salt 
3·2Br was attempted following a modification of the Brust-Schiffrin method[30] (see 
Supplementary Material Section 4 Table S2, entry 6). In the case of 4·2Br, the preparation of the 
AuNPs was attempted by a modification of the Turkevich method[29] using different reduction 
agents such as NaBH4[34], H2O2[35,36] or citrate[29] (see Supplementary Material Table S2, 
entries 7-10). In all cases, using 3·2Br or 4·2Br did not yield any AuNPs, as no formation of the 
typical red solution was observed, and a precipitate was visible in some cases. Clearly, the length 
of the chain of the bis-pyridinium salt, 18 carbon atoms in 1·2Br is decisive for the amphiphile to 
act as promoter agent, and thus to successfully generate AuNPs. Consequently, the use of 3·2Br 
and 4·2Br for the synthesis of AuNPs was not further studied. 
 
 
 
 
Table 1. Experiments for the synthesis of AuNPs with bis-pyridinium salts 1·2Br and the 
tetrahydropyridine 2. 
Entry Sa RAb Au:Sa:RAb RC
c 
T (°C)/solvent 
AuNPs Aspect 
1 1·2Br Citrate 1:8:12 r.t/CHCl3; H2O 1·AuNPs red 
solution 
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2 1·2Br NaBH4 1:2:5 r.t/CHCl3; H2O 2·AuNPs red 
solution 
3 
1·2Brd NaBH4 1:0.5:15 r.t/CHCl3; H2O 3·AuNPs red 
solution 
1·2Brd NaBH4 1:0.5:15 r.t/CHCl3; H2O 4·AuNPs red 
solution 
4 2 - 1:2:0 r.t/CHCl3 - dark 
precipitate 
5 2e - 1:12:0 r.t/CHCl3; H2O 2'·AuNPs red 
solution 
a S: Stabilizer. b RA: Reducing Agent. c RC: Reaction conditions. d In presence of HS-C11-(EG)6-
OH respect to Au0. The number of moles of 1·2Br plus HS-C11-(EG)6-OH is equivalent to the total 
amount of 1·2Br used in previous experiments. e In presence of an excess of KBr respect to Au0. 
Table (1.5-column) 
 
3.2. Characterization of AuNPs from 1·2Br and the tetrahydropyridine 2  
UV-vis absorption spectroscopy of 1·AuNPs-4·AuNPs and 2'·AuNPs in CHCl3 as well as 
3·AuNPs in water showed the typical surface plasmon resonance (SPR) peaks of gold colloids 
between 510 and 526 nm (Figure 2 black, red, dark blue, light blue and green line, respectively) 
which is responsible for their typically coloured solutions. The different SPR peaks obtained for 
the synthesized 1·AuNPs-4·AuNPs and 2'·AuNPs, may be due to the selected synthesis method 
in each GNP and their varied composition. 
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Figure 2. UV-vis absorption spectra of the 1·AuNPs-4·AuNPs and 2'·AuNPs. 
Figure (1.5-column)  
 
High-Resolution Transmission Electron Microscopy (HRTEM). 1·AuNPs-4·AuNPs and 
2'·AuNPs were characterized using HRTEM to study their morphology and their size distribution. 
The samples observed by HRTEM were prepared by depositing onto a carbon-coated copper grid 
the solutions of AuNPs with concentration range between 4x10-4 - 5x10-2 µM. Figure 3 shows the 
micrographs obtained for 1·AuNPs-4·AuNPs and 2'·AuNPs and their respective histograms. In 
all cases, the nanoparticles display a spheroidal shape and low polydispersity (Table 2). The 
samples of 1·AuNPs showed the biggest size and lowest polydispersity, which may be due to the 
selected synthesis method using a Turkevich protocol. Colloids 2·AuNPs and 4·AuNPs showed 
the highest polydispersity with an average size between 5 and 17 nm, while in the cases of 
3·AuNPs and 2'·AuNPs an average size between 9-13 nm was observed (Table 2).  
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Figure 3. HRTEM micrographs of a) 1·AuNPs c) 2·AuNPs, e) 3·AuNPs, g) 4·AuNPs and i) 
2'·AuNPs and, b), d), f), h) and j) are their corresponding histograms. In all cases, the number of 
particle counts was higher than 35. Figure (1.5-column)  
 
Dynamic Light Scattering (DLS). The size of 1·AuNPs, 2·AuNPs, 3·AuNPs, 4·AuNPs and 
2'·AuNPs was also measured using DLS. These AuNPs proved stable in solution and have low 
polydispersity index as shown in the Table 2. The average size measured was between 11.3-23.5 
nm. These results imply a slightly higher diameter than that observed by HRTEM, in agreement 
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with the fact that this technique measures the hydrodynamic size of the particles, in contrast with 
HRTEM that only gives us the gold core size, because no contrast agent was used and the ligands 
used are transparent to the electron beam compared with the gold. Thus, the size measured by DLS 
gives the diameter that includes not only the core but also the alkyl chains of the ligands. 1·AuNPs 
showed the highest value of size (23.5 nm), this result may be due to the selected synthesis method, 
as it is known that the AuNPs synthesized by Turkevich method present a bigger size than the 
AuNPs synthesized by Brust-Schiffrin method. On the other hand, the values of the size obtained 
by DLS were similar for 2·AuNPs and 2'·AuNPs nanoparticles, this may be because both have a 
similar composition, while in the case of 3·AuNPs and 4·AuNPs were bigger, this may be due to 
the presence of S-PEG on the surface of AuNPs, which leads to increase the diameter of the 
nanoparticles.  
NMR spectroscopy. NMR spectroscopy was used to complement the information about the species 
coating the different AuNPs, and the results are in good agreement with those observed by 
MALDI-ToF-MS. The 1H NMR spectra of 1·AuNPs, acquired in CDCl3 at room temperature 
exhibit signals corresponding to the bis-pyridinium salt 1·2Br (see Supplementary Material Figure 
S22). In contrast, in the cases of the 2·AuNPs and 2'·AuNPs, the signals corresponding to the 
tetrahydropyridine 2 were observed (see Supplementary Material Figure S23 and S24, 
respectively). 
 
 
 
 
Table 2. Average size measured by HRTEM, DLS and Pdi for 1·AuNPs-4·AuNPs and 2'·AuNPs. 
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Sample Z-averagea (nm)/ 
HRTEMb ± SDc 
Z-averagea (nm)/ 
DLSd 
Pdie 
1·AuNPs 18.3 ± 0.5 23.5 0.08 
2·AuNPs 5.8 ± 1.3 11.3 0.26 
3·AuNPs 13.5 ± 2.7 17.3 0.13 
4·AuNPs 16.5 ± 2.9 21.2 0.25 
2'·AuNPs 9.7 ± 0.5 13.7 0.17 
a Average size measured. b High-Resolution Transmission Electron Microscopy. c 
Standard deviation. d Dynamic Light Scattering. e Polydispersity index calculated by DLS. 
Table (1.5-column) 
 
Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-ToF-
MS). This technique was used to study the coating of 1·AuNPs-4·AuNPs and 2'·AuNPs, and the 
results are shown in Table 3 (see also Supplementary Material Table S3 and Figure S25-S29, 
respectively). The spectra were recorded using DHB as the matrix. Despite precedents from the 
literature reports,[22,23,25] on bis-imidazolium coated nanoparticles, the experimental conditions 
for recording sufficiently informative spectra were difficult to find. As we can see in Table 3 and 
Table S3 see Supplementary Material, all nanoparticles but 1·AuNPs have multicomponent 
coatings. In the case of 2·AuNPs and 2'·AuNPs there is indication of the presence of both ligands 
1·2Br or 2, peaks arising from the tetrahydropyridine 2 being the most abundant, together with 
peaks resulting from the fragmentation of 1·2Br (see Supplementary Material Table S3). These 
results can be explained in terms of the redox processes taking place during the synthesis of the 
AuNPs leading to the existence of both species in the mixed coatings, i.e. reduction of 1·2Br by 
NaBH4 in the case of 2·AuNPs, or spontaneous oxidation of 2 in the case of 2'·AuNPs. Obviously, 
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for 1·AuNPs, synthesized using citrate as the reducing agent, only peaks associated to the bis-
pyridinium salt 1·2Br can be observed; specifically, peaks corresponding to its the molecular ion 
(m/z 957.6) (Table 3) or peaks resulting from its fragmentation (Table S3 in the Supplementary 
Material); the fragments reveal complexation to gold, indicating close proximity to the surface of 
the nanoparticle metallic core. For multicomponent colloids 3·AuNPs and 4·AuNPs the most 
abundant peaks indicate the presence of both 1·2Br and the thiolated polyethyleneglycol derivative 
as the predominant species, although in the case of 4·AuNPs, the tetrahydropyridine 2 was also 
present, something that could explain the higher hydrophobicity of these nanoparticles because of 
the absence of charge in the reduced surfactant. 
 
Table 3. Positive-Ion Mode MALDI-ToF-MS for the AuNPs 1·AuNPs-4·AuNPs and 2'·AuNPs 
using DHB as matrix. 
ionsa (m/z, %) 
AuNPs [Mb-1H]+ [Mc-H]+ [Md+Na+]+ 
1·AuNPs 957.6 (45 %)   
2·AuNPs  803.8 (100%)  
3·AuNPs 957.6 (90 %)  491.3(100 %) 
4·AuNPs 957.6 (100 %) 803.8 (45%) 491.3 (75 %) 
2'·AuNPs  803.8 (100%)  
a m/z: mass/charge ratio, (%): relative abundance. b 1·2Br. 
c Tetrahydropyridine 2. d HS-C11-(EG)6-OH. Table (1.5-column) 
X-ray Photoelectron Spectroscopy (XPS) was used to determine the valence state of gold in the 
synthesized nanoparticles 2·AuNPs, 3·AuNPs 4·AuNPs and 2'AuNPs. The samples were 
prepared by drop casting of the different AuNPs solutions (CHCl3 or H2O) onto a silicon substrate. 
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For all experiments, sputtering of the samples was necessary to remove the outer organic layer and 
expose the metallic core so that the peaks corresponding to the Au0 could be clearly identified. The 
characteristic binding energies of Au0 at 84.4 and 88.2 eV, corresponding to Au 4f7/2 and Au 4f5/2 
respectively, could be observed for 2·AuNPs, 3·AuNPs and 4AuNPs (see Supplementary Material 
Figure S30). In the case of the 2’·AuNPs it was not possible to observe the signals corresponding 
to Au0 not even after the sputtering step, probably because the coating tetrahydropyridine 2. In the 
case of 2'·AuNPs, 2 forms an extremely compact bilayer around the monolayer of the pyridinium 
salt, which difficult the extraction of the organic layer without completely destroying the sample.  
 
Thermogravimetric Analysis (TGA). 2·AuNPs was further characterized by TGA, to confirm the 
presence of both ligands in these GNP. The thermogram of 2·AuNPs showed the presence of both 
1·2Br and the correspondingly reduced 2 (see Supplementary Material Section 5 Figure S31). 
TGA also allowed determination of the mass ratio for the two ligands (1·2Br and 2) and gold in 
the analysed 2·AuNPs samples, as stated in (Supplementary Material Table S4). Taking into 
account their respective molecular weights, we could determine the number of moles for each 
species, and establish a ratio of stabilizer to gold. Furthermore, considering the size of the gold 
core in 2·AuNPs, the number of gold moles per nanoparticle was determined, and with the ratio 
stabilizer: gold, the number of ligands per nanoparticle was calculated. Also, after calculating the 
nanoparticle’s surface area the presence of ca. 14 molecules of 1·2Br and 19 molecules of 2 per 
nm2 was estimated (see Supplementary Material Figure S31 and Table S4). This density is similar 
to the previously reported AuNPs incorporating gemini imidazolium amphiphiles as stabilizer 
agents.[22,25] Overall, it seems to confirm that the minority ligand 1·2Br forms a layer around 
the gold core, so that the formed 2·AuNPs have the positively charged pyridinium heads layer 
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favouring stabilization of the gold core, and the tetrahydropyridine 2 forms a layer around the bis-
pyridinium salt 1·2Br. This particular disposition would explain why 1·2Br could not be 
noticeably detected by MALDI-ToF MS and 1H NMR spectroscopy. 
3.3. Cytotoxicity and genotoxicity assay of 1·2Br, 2·AuNPs and 3·AuNPs  
The cytotoxicity and genotoxicity of ligand 1·2Br as well as 2·AuNPs and 3·AuNPs were studied, 
since these AuNPs will be used later in the drug release study (see later). The cytotoxicity 
(expressed here as IC50) was determined in three different cell lines; the mouse fibroblast cell line 
(3T3/NIH), the human liver carcinoma cell line (HepG2) and the human epithelial colorectal 
adenocarcinoma cell line (CaCo-2). The cells were exposed to a range of concentrations of ligand 
1·2Br, 2·AuNPs and 3·AuNPs for 24 h. The coated AuNPs after to interact with the cell medium, 
no agglomeration or turbidity was observed, indicating that the synthetized gold nanoparticles 
2·AuNPs and 3·AuNPs were stably dispersed in the cell medium for the cytotoxicity test. After 
exposure, the viability of the cell culture was calculated using the MTT Assay, and the percentage 
of viable cells was determined as shown in the Supplementary Material Section 6 (Tables S5-S7). 
The IC50 concentration values calculated for ligand 1·2Br as well as for 2·AuNPs and 3·AuNPs 
are shown in Table 4. The IC50 values found from 2·AuNPs and 3·AuNPs were lower than the 
IC50 value obtained for the amphiphiles 1·2Br alone. These results suggests that the interaction of 
the polar head group with the gold nucleus of the nanoparticles prevents, in some way, a higher 
toxicity, presumably because the positive charge of the pyridinium salt is shielded from interaction 
with the cell.[37,38] In the case of 2·AuNPs, they were not cytotoxic for any cell line used, 
whereas 3·AuNPs showed very low toxicity in HepG2 and CaCo-2 at high concentrations (418 
µM and 10460 µM, respectively). Comparison of the values found in the literature for cytotoxicity 
of gold nanoparticles is hampered by the different experimental protocols reported for its 
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evaluation, as well as for the differences in the composition of the nanomaterials, for which a 
precise composition is not always defined.[39] Several reports indicate that interaction with the 
biological media depends on many factors, such as size, shape and charge of gold 
nanoparticles.[40] Additionally, the moderate toxicity of cationic particles has been evaluated,[41] 
with the toxicity mainly attributed to the cationic surfactant used as coating agent.[42] 
 
Table 4. Values of the IC50 determined for the products tested in three different cell lines.  
 
Products 
Cell line 3T3 Cell line HepG2 Cell line CaCo-2 
IC50 
(µg/mL) 
IC50 
(µM) 
IC50 
(µg/mL) 
IC50 
(µM) 
IC50 
(µg/mL) 
IC50 
(µM) 
1·2Br 250 96 70 73 > 500 1833 
2·AuNPs > 500 > 500 > 500 > 500 > 500 > 500 
3·AuNPs > 500 > 500 611 418 > 500 10460 
The maximum concentration tested was 500 µg/mL. Table (1.5-column) 
 
To be suitable for drug delivery purposes, the carriers themselves must be biocompatible and 
present low toxicity. In our work, it was found that these AuNPs (2·AuNPs and 3·AuNPs), showed 
low toxicity in three studied cell lines, since the values found for the IC50 were ca. 0.5-1 mM. 
These are very high values taking into consideration they are well above the expected 
concentrations to be administered, which means that the AuNPs should be safe.  
Additionally, to evaluate the genotoxicity of 1·2Br, 2·AuNPs and 3·AuNPs in three cell line 
(3T3/NIH, HepG2 and CaCo-2), the Single Cell Gel Electrophoresis, also known as Comet Assay, 
was used according to guidelines.[43] For this analysis, cell viability higher than 70 % was 
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required and a genotoxic effect was considered for tail intensity values higher than 10 %. The 
DNA-damaging alkylating-agent methylmethane sulfonate (MMS 400 mM) was used as positive 
control. Table S5-S7 in the Supplementary Material show the percentage of tail intensity referring 
to the DNA fragmentation in the presence of amphiphile 1·2Br, 2·AuNPs and 3·AuNPs, at the 
same range of concentrations used for testing their cytotoxicity. It was observed that neither 1·2Br 
nor the AuNPs (2·AuNPs and 3·AuNPs) show any significant formation of a tail of cellular DNA 
fragments within the studied concentrations and cell lines tested, which means that below the IC50 
no genotoxicity is observed (see Supplementary Material Tables S5-S7), confirming the suitability 
of these nanomaterials for drug delivery purposes. 
 
3.4. Incorporation of ibuprofen and piroxicam into different AuNPs (organic and water 
soluble) 
Prior to the incorporation study of ibuprofen and piroxicam into different AuNPs was study the 
complexation ability of the bis-pyridinium amphiphile 1·2Br to ibuprofen and piroxicam was 
examined in solution, using 1H NMR spectroscopy. The binding of 1·2Br with piroxicam appears 
to be the stronger as indicated by the observed chemical shifts (see Supplementary Material 
Section 7 Figure S32 and Table S8). 
The synthesis of 5·AuNPs and 6·AuNPs  (see Supplementary Material Section 8 Figure S33) was 
necessary to use as control nanoparticles in the incorporation study of drugs such as ibuprofen, 
piroxicam and their respective sodium salts (see later). In both cases, the obtained 5·AuNPs and 
6·AuNPs display a spheroidal shape and low polydispersity (Figure S34 and Table S9 in the 
Supplementary Material Section 8). 
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After evaluation of the anion binding exhibited by the pyridinium salt 1·2Br, we decided to 
investigate if the binding ability was still operating in the AuNPs prepared in this work. Initially, 
the anion binding properties of 2·AuNPs, 3·AuNPs, 4·AuNPs, as well as the non-pyridinium 
containing controls 5·AuNPs and 6·AuNPs were studied by UV-vis absorption spectroscopy. 
The quantification of ibuprofen and piroxicam were carried out by UV-vis absorption 
spectroscopy, and used to evaluate the incorporation of these drugs into water soluble 3·AuNPs 
and 5·AuNPs; their corresponding sodium salts (ibuprofen sodium salt and piroxicam sodium 
salt), were incorporated into organic-soluble 2·AuNPs, 4·AuNPs and 5·AuNPs.  
The results of drug incorporation in different nanoparticles are shown in Table 5. Control 
extraction experiments using only solvent as the extraction phase (without any nanoparticles) 
indicated that, the quantity of drug in solution was similar to that obtained in the initial solution. 
These results indicated that the solvent (H2O/CHCl3) does not interfere with the incorporation of 
drugs into nanoparticles.  
In the case of 2·AuNPs (organic-soluble AuNPs), the percentage of piroxicam sodium salt 
incorporated to them was greater than ibuprofen sodium salt (Table 5), possibly because of the 
higher affinity between piroxicam sodium salt and the ligand 1·2Br as the study of drug-ligand 
interaction by NMR had shown.  
A similar trend is observed for the AuNPs with both ligand 1·2Br and the pegylated thiol 
(3·AuNPs and 4·AuNPs), which showed higher values of incorporated piroxicam or piroxicam 
sodium salt rather than either ibuprofen or its sodium salt.  
At this point, a control was performed with nanoparticles 5·AuNPs and 6·AuNPs, incorporating 
only the pegylated thiol, but not the gemini-pyridinium salt 1·2Br. The incorporation of the 
piroxicam drug was evaluated showing extremely low percentages of incorporation in both 
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nanoparticles 5·AuNPs and 6·AuNPs with values of 8 and 25 %, respectively, indicating that 
1·2Br present in the nanoparticles is by far the main responsible for the incorporation of the drug 
in the nanoparticles synthesized 2·AuNPs, 3·AuNPs and 4·AuNPs.  
 
Table 5. Percentages of anionic drug incorporated in different gold nanoparticles.  
 
AuNPs 
Drug incorporation (%)n 
Ibuprofen 
(sodium salt) 
Ibuprofen Piroxicam 
(sodium salt) 
Piroxicam 
2·AuNPs (a) 13.6 ± 4.0 n/d 46.3 ± 2.3 n/d 
3·AuNPs (b) n/d 19.3 ± 2.6 n/d 78.3 ± 4.0 
4·AuNPs (a) 17.0 ± 3.0 n/d 73.6 ± 3.9 n/d 
n number of replicates. n/d = not determined, results displayed as average with error 
corresponding to standard deviation, obtained for n=3 independent experiments.  
Table (1.5-column) 
 
Accordingly, the bis-pyridinium salt 1·2Br containing nanoparticles 3·AuNPs (water-soluble) and 
4·AuNPs (organic-soluble) were used for in vitro studies of piroxicam or piroxicam sodium salt. 
In order to know the concentration of 3·AuNPs and 4·AuNPs we applied calculations described 
by Haiss (see Supplementary Material Section 9).[44] The final concentration of 3·AuNPs was 
170 nM, and 143 nM from 4·AuNPs. After the extraction, in the case of 3·AuNPs the aqueous 
phase was washed three times with dichloromethane and in the case of 4·AuNPs the organic phase 
was washed three times with water, to remove any unbound drug (piroxicam and piroxicam sodium 
salt). The aqueous phase with the 3·AuNPs and piroxicam incorporated exhibits, besides the 
3·AuNPs peak at 522 nm, the peak at 342 nm corresponding to piroxicam (see Supplementary 
 29 
Material Figure S35 a)). This peak was not visible in the organic phases used to extract piroxicam 
from the nanoparticles. On the other hand, from the organic phase with the 4·AuNPs and 
piroxicam sodium salt incorporated exhibits, besides the 4·AuNPs peak at 528 nm, the peak at 324 
nm corresponding to piroxicam (see Supplementary Material Figure S35 b)). This peak was not 
visible in the aqueous phases used to extract the piroxicam sodium salt from the nanoparticles. 
This means that the drug was well incorporated into the nanoparticles, and that the pyridinium 
ligands can bind enolate incorporating compounds. Also, a slight change in the SPR peak of the 
AuNPs was registered, that initially was at 518 nm and shifted to 522 nm for 3·AuNPs and 519 
nm and shifted to 528 nm for 4·AuNPs. It is known that the SPR peak depends not only of the size 
of the AuNPs but also of the ligand that is covering the AuNPs, so we could explain this shift 
because of the incorporation of the drug (piroxicam and its sodium salt) in the structure. According 
to our calculations, we could incorporate 50 μg of piroxicam/mg in 3·AuNPs and 46 μg of 
piroxicam sodium salt/mg in 4·AuNPs.  
Finally, the stability of the water soluble 3·AuNPs after the incorporation of piroxicam was studied 
for a period of three months, and no macroscopic changes in the colloidal dispersions or variations 
in the SPR band were observed, which indicates that their stability was not affected after the 
incorporation of the drug (see in the Supplementary Material Table S10). 
3.5. In vitro release studies 
The release of piroxicam from the AuNPs was determined using a Franz cells system as schematic 
representation is included in Figure S36 in the Supplementary Material Section 1.[45] The samples 
were suspended in Sorensen buffer at either pH 5.5 or 7.4, to simulate physiological conditions, 
and the receptor solution used was NaOH 71 mM, in which piroxicam is soluble, as tested prior to 
the experiments, and thus complying with the SINK conditions. Given the size of the gold 
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nanoparticles, dialysis membranes were selected with a cut-off which allows the passage of 
piroxicam (molecular weight 331.35 Da) but prevents the passage of the nanoparticles (membrane 
dialysis pore diameter is equivalent to 2.4 nm).  
Six different kinetic models (zero order, first order, Plateau followed by a first order , Korsmeyer- 
Peppas, Higuchi and Weibull function) were used to fit the experimental data obtained in the drug 
release experiments following the corresponding equations (see Table S11 in the Supplementary 
Material). The kinetic model that best describes the release of piroxicam and sodium salt piroxicam 
respectively, from 3·AuNPs and 4·AuNPs, for both pH values tested, is the Plateau followed by 
a first order  model as shown in Figure S37 in the Supplementary Material. This means that the 
release rate depends only on the amount of drug present. Furthermore, the presence of a delay in 
the beginning of the release means that the drug is well encapsulated by the ligand 1·2Br, and 
suffers other diffusion processes from the interior of the nanoparticle, specifically a partition 
between the inner environment and the donor solution. This partition favours the slow release of 
the drug, because the donor solution must comply with the physiological conditions, opposite to 
the receptor solution. Additionally, is know that the piroxicam is more soluble in aqueous solution 
at pH 7.4 (similar to physiological conditions) than in solutions at acidic pH, which is favoured by 
the ionization of the drug at pH 7.4.[46] This intrinsic characteristic of the drug does not favour 
the diffusion process from the interior of the nanoparticle, resulting in a delayed release of the drug 
at pH 5.5 respect to 7.4. 
At physiological conditions the drug release followed a first order kinetics (Figure 4), with values 
of the dissociation constant KD of 0.0129 h
-1 and 0.0100 h-1 from 3·AuNPs and 4·AuNPs, 
respectively. At pH 5.5, the same kinetics were observed, and the dissociation constant found were 
0.0095 h-1 and 0.0034 h-1 from 3·AuNPs and 4·AuNPs, respectively.  
 31 
Additionally, the amodelistic parameters (efficiency, medium dissolution time (MDT) and area 
under curve (AUC)) were calculated (Supplementary Material Section 10, Table S12). Therefore, 
Student´s t-test analysis was performed and significant differences were found between the 
releases at the pH 5.5 and 7.4 (see Supplementary Material Table S13). At pH 7.4 the efficiency 
of the release is higher than at pH 5.5 in both AuNPs (3·AuNPs and 4·AuNPs), meaning that it is 
more suited for delivery under physiological conditions and not for an external application in the 
skin since a higher amount of drug can be released from the AuNPs. On the other hand, the value 
of MDT registered at pH 7.4 is lower, suggesting that the release of this drug from the AuNPs 
complex is favoured at this pH. Moreover, in the case of the water-soluble 3·AuNPs the release of 
the drug is more favoured than 4·AuNPs. This can be seen as an advantage of 3·AuNPs, allowing 
its use as nanosystems with a high potential for use in biomedical applications. 
 
 
a)
b)
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Figure 4. a) Liberation profile at pH 7.4 and 5.5 of piroxicam-3·AuNPs, b) Liberation profile at 
pH 7.4 and 5.5 of piroxicam sodium salt-4·AuNPs. Results displayed as an average with error bars 
corresponding to standard deviation obtained for n=3 independent experiments.  
Figure (1.5-column) 
 
Additionally, two stability experiments in aqueous solution of 3·AuNPs before and after the 
incorporation of piroxicam were performed for a period of a week. The piroxicam-3·AuNPs were 
dissolved in three buffer solutions at either pH 5.5, 7.4 and 9, at room temperature and at 37°C.  
Any case no macroscopic changes in the colloidal dispersions or variations in the SPR band and 
in the corresponding band of the drug were observed, which indicates that the 3·AuNPs are stable 
at different pH under the described conditions and they were not affected after the incorporation 
of the drug (see in the Supplementary Material Section 11 Tables S14 and S15, respectively). 
Obviously, the complex would be coated AuNPs-piroxicam will be no longer existing when upon 
release conditions (see above, in vitro release studies). 
 
4. Conclusions 
In this work, we have synthesized and characterized three bis-pyridinium salts 1·2Br, 3·2Br, and 
4·2Br with different chain lengths (18, 10 and 1 carbon atoms, respectively). Clearly, the length 
of the chain of the bis-pyridinium salt, is decisive for the amphiphile to act as promoter agent, 
since only 1·2Br containing 18 carbon atom chains are able to successfully generate 2·AuNPs 
following a biphasic method.[30] Consequently, the use of 3·2Br and 4·2Br for the synthesis of 
AuNPs is not favourable. The tetrahydropyridine moiety in 2 (resulting from the reduction of 
1·2Br) is capable of reducing Au+3 to Au0, due to its spontaneous oxidation to the pyridinium salt, 
leading to the formation of 2'·AuNPs. The gold nanoparticles synthesized 1·AuNPs-4·AuNPs 
and 2'·AuNPs proved stable and to have low polydispersity. Remarkably, 2'·AuNPs were found 
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to be stable and monodisperse only when synthesized in the presence of KBr, indicating not only 
how crucial are the long chains in the amphiphile but the critical role of anions in their structure 
for the synthesis and stability of these nanoparticles, as described in previous report.[22,33] The 
close proximity of the ligand 1·2Br to the metallic core was confirmed by different techniques 
such as MALDI-ToF MS and NMR spectroscopy. The ligand 1·2Br as well as 2·AuNPs and 
3·AuNPs were neither cytotoxic nor genotoxic to the cell lines studied (3T3/NIH, HepG2 and 
CaCo-2) at the concentrations tested, when compared with similar structures using the same cell 
lines.[23] Additionally, 3·AuNPs and 4·AuNPs incorporating both 1·2Br and HS-C11-(EG)6-OH 
encapsulate piroxicam and piroxicam sodium salt, and release it in a sustained manner, suggesting 
that it diffuses from the complex instead of being released with an initial burst. This means that 
these vehicles could be used for long-term delivery of the drug. Moreover, the incorporation of 
piroxicam was evaluated and showed extremely low percentages of incorporation in both non-
pyridinium coated nanoparticles 5·AuNPs and 6·AuNPs, indicating that the bis-pyridinium 
functionalization present in 2·AuNPs, 3·AuNPs and 4·AuNPs is by far the main factor 
determining the incorporation of the drug. Additionally, 3·AuNPs and 4·AuNPs showed the 
ability to incorporate piroxicam and piroxicam sodium salt respectively, with no significant 
differences in the amount of drug encapsulated. Moreover,the in vitro release of 3·AuNPs and 
4·AuNPs at two different pH values (7.4 and 5.5) proves a faster release profile at pH 7.4, 
indicating their suitability as promising materials for delivery in physiological conditions. Finally, 
3·AuNPs resulted stable at different pH under the described conditions and they were not affected 
after the incorporation of the drug . The next step in this research would be incorporation of other 
anionic drugs of higher therapeutic interest and testing the in vivo efficacy through alternative to 
oral administration in order to convert the AuNPs from a delivery vehicle into a theranostics tool. 
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